Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 14
1946 59
1947 73
1948 72
1949 65
1950 112
1951 135
1952 154
1953 161
1954 151
1955 153
1956 134
1957 95
1958 108
1959 89
1960 113
1961 98
1962 110
1963 187
1964 207
1965 163
1966 161
1967 153
1968 188
1969 168
1970 142
1971 137
1972 133
1973 116
1974 101
1975 92
1976 74
1977 68
1978 82
1979 59
1980 59
1981 45
1982 45
1983 75
1984 55
1985 81
1986 38
1987 32
1988 35
1989 27
1990 36
1991 29
1992 16
1993 21
1994 29
1995 22
1996 31
1997 19
1998 30
1999 29
2000 21
2001 53
2002 33
2003 28
2004 39
2005 66
2006 54
2007 56
2008 68
2009 72
2010 91
2011 78
2012 122
2013 150
2014 115
2015 117
2016 146
2017 131
2018 134
2019 95
2020 16
Text availability
Article attribute
Article type
Publication date

Search Results

6,279 results
Results by year
Filters applied: . Clear all
Page 1
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M. Poeppel TD, et al. Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12. Eur J Nucl Med Mol Imaging. 2018. PMID: 29234845
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators. Sartor O, et al. Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28. Oncologist. 2018. PMID: 29183960 Free PMC article. Clinical Trial.
Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer.
Unda-Urzaiz M, Sousa-Campo R, Rodríguez-Antolín A, Silva-Marins C, Juárez-Soto A, Miñana-López B, Figueiredo-de Castro A, Cozar-Olmos JM. Unda-Urzaiz M, et al. Actas Urol Esp. 2018 May;42(4):227-237. doi: 10.1016/j.acuro.2017.05.005. Epub 2017 Jul 12. Actas Urol Esp. 2018. PMID: 28711312 Review. English, Spanish.
Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.
van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. van der Doelen MJ, et al. Clin Genitourin Cancer. 2019 Apr;17(2):79-87. doi: 10.1016/j.clgc.2018.11.008. Epub 2018 Nov 22. Clin Genitourin Cancer. 2019. PMID: 30558834 Review.
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F. Heidenreich A, et al. BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y. BMC Cancer. 2019. PMID: 30612558 Free PMC article. Clinical Trial.
Radium 223 dichloride for prostate cancer treatment.
Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N. Deshayes E, et al. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. doi: 10.2147/DDDT.S122417. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28919714 Free PMC article. Review.
6,279 results
Jump to page
Feedback